Piper Jaffray analyst David Amsellem reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) yesterday and set a price target of $24. The company’s shares opened today at $17.05.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.9% and a 45.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.45 and a one-year low of $14.40. Currently, Amphastar Pharmaceuticals has an average volume of 229.6K.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.
